Home > Insider Trading > Filing (0000899243-23-004411)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1690585	Magenta Therapeutics Inc.	MGTA	()	DE

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1688325	Trv Gp Iv, Llc	201 Brookline Ave, Suite 1401 Boston MA 02215	No	No	Yes	No
1688326	Third Rock Ventures Gp Iv, L.p.	201 Brookline Ave, Suite 1401 Boston MA 02215	No	No	Yes	No
1688327	Third Rock Ventures Iv, L.p.	C/O Third Rock Ventures, Llc 201 Brookline Ave, Suite 1401 Boston MA 02215	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2023-02-07	2,200,000	$0.83	4,558,204	No	4	S	Direct
Common Stock	Disposition	2023-02-08	1,500,000	$0.82	3,058,204	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Direct

Footnotes

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.808 to $0.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1).
These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.801 to $0.893, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3).